Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Intercellular adhesion molecule-1 in the heart.

Hans W M Niessen1, Paul A J Krijnen, Cees A Visser

  • 1Department of Pathology, ICaR-VU, VU University Medical Center, Amsterdam, the Netherlands. jmw.niessen@vumc.nl

Annals of the New York Academy of Sciences
|December 18, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Structure-function analysis of empasiprubart, a calcium- and pH-dependent clinical phase complement C2 blocking antibody.

mAbs·2026
Same author

Development of an anti-rat complement C2 antibody that improves renal outcome in a rat kidney transplant model.

Frontiers in immunology·2026
Same author

IgM Anti-Ganglioside Binding and Complement Activation in an iPSC-Derived Motor Neuron Model for Multifocal Motor Neuropathy.

Neurology(R) neuroimmunology & neuroinflammation·2025
Same author

Randomized phase I trial outcomes show safe and sustainable inhibition of classical and lectin complement pathways by empasiprubart.

Nature communications·2025
Same author

Complement activation by IgM autoantibodies linked to immune-mediated neuropathies depends on C2.

European journal of neurology·2024
Same author

IgM anti-GM2 antibodies in patients with multifocal motor neuropathy target Schwann cells and are associated with early onset.

Journal of neuroinflammation·2024

Intercellular adhesion molecule-1 (ICAM-1) is upregulated in heart attacks. Inhibiting ICAM-1 in the heart significantly reduces damage, suggesting it as a potential therapy for myocardial infarction.

Area of Science:

  • Cardiovascular biology
  • Immunology
  • Molecular medicine

Background:

  • Intercellular adhesion molecule-1 (ICAM-1) is an immunoglobulin superfamily adhesion molecule.
  • ICAM-1 expression is increased in various pathophysiological conditions.
  • Cardiomyocytes can express ICAM-1, particularly during acute myocardial infarction.

Purpose of the Study:

  • To investigate the role of ICAM-1 in acute myocardial infarction.
  • To evaluate the therapeutic potential of ICAM-1 inhibition in reducing infarct size.

Main Methods:

  • The abstract does not specify methods, but implies studies involving ICAM-1 expression in cardiomyocytes and the effects of its inhibition on infarct size.

Main Results:

Related Experiment Videos

  • ICAM-1 is expressed by cardiomyocytes in acute myocardial infarction.
  • Inhibition of ICAM-1 expression in the heart leads to a significant reduction in infarct size.

    • Conclusions:

    • ICAM-1 plays a role in the pathophysiology of acute myocardial infarction.
    • Targeting ICAM-1 may represent a novel therapeutic strategy for managing myocardial infarction.